Pankomab

PankoMab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.[1] PankoMab is being developed by Glycotope GMBH [2] and is currently undergoing a phase II clinical trial for ovarian cancer [3]

Pankomab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targettumor specific glycosylation of MUC1
Clinical data
Other namesPankoMab-GEX, anti-TA-MUC1
ATC code
  • none
Identifiers
ChemSpider
  • none

References
  1. http://www.cancer.gov/drugdictionary?cdrid=687630
  2. https://www.glycotope.com/pipeline/pankomab-gex
  3. http://clinicaltrials.gov/ct2/show/NCT01899599


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.